Trombopag 50mg tablet

Immune thrombocytopenia (ITP) is a rare blood disorder characterized by a low platelet count. This deficiency in platelets can lead to bruising and excessive bleeding.

People with immune (primary thrombocytopenia (ITP)) and children under one should not use Rompag 50mg tablets. Additionally, individuals with severe aplastic anemia and hepatitis C should not use it.

Yes, you will be closely monitored while taking eltrombopag tablets. Your healthcare provider will routinely assess your white blood cell count, platelet levels, blood clotting factors, heart rate, and vision and perform a complete blood count (CBC).

Yes, eltrombopag tablets should be taken on an empty stomach. This is because antacids, mineral and vitamin supplements (such as iron, calcium, magnesium, aluminum, selenium, and zinc), dairy products, calcium-enriched foods, and fortified juices can interfere with the absorption of the medication. It is recommended to take these substances at least two hours before or four hours after taking Rompag 50mg tablets.

Discontinuing eltrombopag tablets may lead to a decrease in platelet levels, potentially increasing the risk of bleeding or bruising. It is important to consult your healthcare provider before stopping the medication, as they can provide guidance and monitor your condition to prevent complications.

Eltrombopag olamine, commonly sold under the brand name Promacta, is a medication used to treat thrombocytopenia, or low platelet levels. It is a thrombopoietin receptor agonist that stimulates the bone marrow to produce more platelets by binding to the thrombopoietin receptor.

Eltrombopag is a thrombopoietin receptor agonist that stimulates platelet production. Its mechanism of action involves binding to the thrombopoietin receptor (TPO-R), also known as c-Mpl, which is found on the surface of megakaryocyte progenitor cells in the bone marrow. This binding activates intracellular signaling pathways, including the JAK-STAT and MAPK pathways, promoting the proliferation, differentiation, and maturation of megakaryocytes, which in turn leads to increased platelet production. Unlike endogenous thrombopoietin, eltrombopag binds to a different site on the TPO receptor, ensuring it does not compete with natural thrombopoietin while still mimicking its effects. This makes it effective in conditions such as immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, and severe aplastic anemia.